參考文獻 |
1. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004 May 22;363(9422):1711–20
2. Lin, I-Chan, et al. "Glaucoma, Alzheimer′s Disease, and Parkinson′s Disease: An 8-Year Population-Based Follow-Up Study." (2014): e108938.
3. Jørgensen, H., et al. "Stroke in patients with diabetes. The Copenhagen Stroke Study." Stroke 25.10 (1994): 1977-1984. [14]
4. Chen, Hung-Lin, and Fei-Yuan Hsiao. "Risk of hospitalization and healthcare cost associated with Diabetes Complication Severity Index in Taiwan′s National Health Insurance Research Database." Journal of Diabetes and its Complications 28.5 (2014): 612-616.
5. Amos AF, McCarty DJ, Zimmet P: The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 14 (Suppl. 5):S1–S85, 1997
6. Asfandiyarova, Nailya, et al. "Risk factors for stroke in type 2 diabetes mellitus." Diabetes and Vascular Disease Research 3.1 (2006): 57.
7. Lin, Herng-Ching, et al. "Urbanization and stroke prevalence in Taiwan: analysis of a nationwide survey." Journal of Urban Health 84.4 (2007): 604-614.
8. Baliga, Bantwal Suresh, and Jesse Weinberger. "Diabetes and stroke: part one—risk factors and pathophysiology." Current cardiology reports 8.1 (2006): 23-28.
9. Wolf, Philip A., et al. "Probability of stroke: a risk profile from the Framingham Study." Stroke 22.3 (1991): 312-318.
10. Ho, Jau-Der, Chao-Chien Hu, and Herng-Ching Lin. "Open-Angle Glaucoma and the Risk of Stroke Development A 5-Year Population-Based Follow-Up Study." Stroke 40.8 (2009): 2685-2690.
11. French, Dustin D., and Curtis E. Margo. "Open Angle Glaucoma and Stroke." Ophthalmology 117.8 (2010): 1653-e3.
12. Ottenbacher, Kenneth J., et al. "Diabetes mellitus as a risk factor for stroke incidence and mortality in Mexican American older adults." The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59.6 (2004): M640-M645.
13. Zakikhani, Mahvash, et al. "Metformin is an AMP kinase–dependent growth inhibitor for breast cancer cells." Cancer research 66.21 (2006): 10269-10273.
14. Stolar, Mark W., et al. "Managing type 2 diabetes: going beyond glycemic control." Journal of Managed Care Pharmacy 14.5 (2008).
15. Bowker, S. L., et al. "Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure." Diabetologia 53.8 (2010): 1631-1637.
16. DeFronzo, Ralph A. "Pharmacologic therapy for type 2 diabetes mellitus." Annals of internal medicine 131.4 (1999): 281-303.
17. Kendall, David M., et al. "Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea." Diabetes care 28.5 (2005): 1083-1091.
18. D′Hoore, William, André Bouckaert, and Charles Tilquin. "Practical considerations on the use of the Charlson comorbidity index with administrative data bases." Journal of clinical epidemiology 49.12 (1996): 1429-1433.
19. Hsu, Chih-Cheng, et al. "Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin." Journal of Alzheimer′s disease: JAD 24.3 (2010): 485-493.
20. Johnson, Jeffrey A., et al. "Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes." Diabetes care 25.12 (2002): 2244-2248.
21. Tzoulaki I, Molokhia M, Curcin V, Little MP, Millett CJ, Ng A, Hughes RI, Khunti K, Wilkins MR, Majeed A, Elliott P (2009) Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. BMJ 339, b4731.
22. Olsson, J., et al. "Increased mortality in Type II diabetic patients using sulphonylurea and metformin in combination: a population-based observational study." Diabetologia 43.5 (2000): 558-560.
23. Uwaifo GI, Ratner RE. Differential effects of oral hypoglycemic agents on glucose control and cardiovascular risk. Am J Cardiol. 2007;99:51B-67B.
24. Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006; 29:1963-72.
|